+++ HYAL +++ Xnet +++ Sagamore +++ - 500 Beiträge pro Seite

[Leunam]

Hyal: Die FDA zulassung in USA soll noch diesen Monat erfolgen.
Kursziel 18 $ bis ende des Jahres.

Xnet: Erst Kaufen wenn es bis 1 Euro gefallen ist, hat langfristig potential, zu zeit noch sehr risikoreich. Auf sich von 1 bis 2 Jahre wenn alle rechslagen klar sind konnen Kurse von 30 bis 70 $ erwartet werden.

Sagamore: Mann sollte auf den Fahrerende Zug Aufspringen, Kursziel bei 15 bis 18 $ in 1 Jahr.

[floriank]

Super, hab einfach auf dich gehort.
Hast recht gehabt mit sagamore, hoffen wir auch noch das beste für Hyal.

[Specki]

Geht der Blödsinn mit Hyal wieder los oder ist da was drann. Habe auch noch von dem Mist. Wollte Sie schon den Kindern zum Monopolispiel geben.

[WannaBeRich]

Was mich mal interessieren würde, ist die Grundlage der Aussage daß die FDA-Zulassung im April erfolgen soll. Meinem Kenntnis zufolge ist die Zulassung nicht vor Herbst zu erwarten, und bis dahin ist fraglich ob / wie Hyal dann überhaupt noch steht.

[floriank]

Solarase von Hyal soll jetzt duch die FDA auch noch kosmetische Wirkung haben.
Nachzulesen im Consors-Bord und im Hyalforum.
Heilen und noch dazu Verschonen ech Super.

[Schimmelbusch]

test hyal

[Schimmelbusch]

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

[Schimmelbusch]

Der Entwickler und Hersteller von pharmazeutischen Produkten HYAL PHARMACEUTICAL (Kanada) wurde im Sommer 1998 häufig in den populären Aktien-Internetboards als "todsichere 100%-Chance" empfohlen. Damals notierte die Aktie bei etwa bei 3 DM. Jetzt haben die kanadischen Chefs einem Barabfindungsangebot in Höhe von CD$ 0.08 (etwa 0.05 Euro) durch die kanadische Firma Cangene zugestimmt. Davon werden die Aktionäre, die seit Mitte `98 "durchgehalten" haben, nicht gerade begeistert sein. Verlust für sie: ca. 95%. Die "100%-Chance" war also nicht so abwegig...

[Schimmelbusch]

Die Gesellschaft wird von einem äußerst branchenerfahrenen Managementteam geleitet. Der CEO
Alan Drizen war maßgeblich am Aufbau von Hyal Pharmaceutical beteiligt, die mit einer
Marktkapitalisierung von bis zu einer Milliarde US-$ bewertet und später durch Skyepharma
übernommen wurde.

Researchstudie:
General Research GmbH
Analyst: Dr. Georg Hochwimmer

[Schimmelbusch]

Inventors: Drizen; Alan (Downsview, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Appl. No.: 128175
Filed: December 3, 1987

[Schimmelbusch]

http://www.mfcbancorp.com/investor/news_02.08.00.htm




Special Meeting of the Shareholders of Hyal Pharmaceutical Corporation Seeks to Re-Establish Shareholder Representation

GENEVA, Switzerland, February 8, 2000 - - MFC Bancorp Ltd. (Nasdaq: MXBIF and Frankfurt Stock Exchange: MFCGR) announced today that it has, as a shareholder of Hyal Pharmaceutical Corporation ("Hyal", TSE and Nasdaq BB: HYALF), called a Special Meeting of the Shareholders of Hyal to be held on February 25, 2000 pursuant to an Order from the Superior Court of Justice in Ontario.

[Schimmelbusch]

Cade Struktur Corporation Profile

Cade Struktur Corporation - http://www.hyal.com/
204 Black Street
Whitehorse, YUKON TERRITORY Y1A 2M9
CANADA [phone]
[phone]

Cade Struktur Corporation Formerly known as Hyal Pharmaceutical Corpn. The Group`s principal activities are to develop, finance and complete industrial and infrastructural projects in eastern Germany. The Group focuses on structuring the finance to minimize equity requirements through maximum use of subsidies.



CADE STRUKTUR CORPORATION PEOPLE:

President - Jimmy S.H. Lee
Secretary - Greg Elderkin

[Schimmelbusch]

Hyal Pharmaceutical Corp. Announces Name Change to Cade Struktur Corp.
July 31, 2001
Hyal Pharmaceutical Corp. announced that it has changed its name to Cade Struktur Corp.
Hyal Pharmaceutical Corporation Updates Proposal Status
April 19, 2001
Hyal Pharmaceutical Corporation provided an update on the status of the proposal made by the Company under the Bankruptcy and Insolvency Act and approved by the Superior Court of Justice of Ontario on May 31, 2000. Pursuant to the Proposal, the Proposal Trustee has now paid all secured claims, preferred claims and other fees and expenses related to the receivership in full and has distributed all remaining funds held by the Proposal Trustee to unsecured ordinary creditors. Unsecured ordinary creditors received $0.90 for each dollar of approved claims. The remaining amount of unpaid claims, being approximately $1.4 million, are being satisfied in full through the issuance of 10,050,463 common shares of Hyal pursuant to the terms of the Proposal. The Company has also issued $1 million of Preferred Shares, which have a 6% cumulative annual dividend, are redeemable by the Company after a period of two years and are convertible at the holder`s option into common shares of the Company at a price equal to 90% of the average closing price of the common shares for the 10 business days preceding notice of conversion, not to exceed 40% of the total outstanding common shares of the Company. Until such time as the Preferred Shares are converted or redeemed, they will have the right to cast a number of votes equal to 40% of the eligible votes at any meeting of shareholders of the Company.
Hyal Pharmaceutical Corporation Announces New Corporate Direction And Name Change
February 15, 2001
Hyal Pharmaceutical Corporation announced that it will be seeking shareholder approval to change its name to "Cade Stuktur Corporation" to pursue the financing and development of infrastructure related projects in the former East Germany. The Company also announced that it had entered into an agreement with ZPR Zellstoff-und Papierfabrik Rosenthal Holding GmbH (ZHG), whereby ZHG would subscribe for 10 million common shares of the Company, would provide certain management and support to the Company, and would agree not to compete with the Company in its new business. The Company further announced that it had reached an agreement with Prada Holdings Ltd. to acquire a mineral royalty in the Wabush Iron Ore Mine.

[Schimmelbusch]

last and best:

Continued Subsidies from the German Government

The Company`s business plan is significantly dependent on the availability of various types of subsidies for investments in the former East Germany. Currently, the new federal states of eastern Germany offer among the highest financial packages available under European Union regulations to promote investment in eastern Germany. However, the present package of subsidies is in effect only until 2004 and there is no assurance that they will be continued or replaced with equally attractive programs. In addition, as Germany is part of the European Union, it is bound by European Union law, which could mandate that the present package of subsidies be discontinued. If the subsidies are discontinued and not replaced, this would likely have a material adverse effect on the Company`s business.